NBQX
From Infogalactic: the planetary knowledge core
200px | |
Names | |
---|---|
IUPAC name
2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline -7-sulfonamide
|
|
Identifiers | |
118876-58-7 | |
ChEMBL | ChEMBL222519 |
ChemSpider | 2521927 |
4264 | |
Jmol 3D model | Interactive image |
KEGG | C13667 |
PubChem | 3272524 |
|
|
|
|
Properties | |
C12H8N4O6S | |
Molar mass | 336.281 |
Appearance | brown/red powder |
Soluble to 100 mM in DMSO | |
Vapor pressure | {{{value}}} |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
verify (what is ?) | |
Infobox references | |
NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione) is an AMPA receptor antagonist.
NBQX blocks AMPA receptors in micromolar concentrations (~10–20 µM) and also blocks kainate receptors. In experiments, it is used to counter glutamate excitotoxicity.[1] NBQX was found to have anticonvulsant activity in rodent seizure models.[2]
As the disodium salt, NBQX is soluble in water at high concentrations (at least up to 100 mM).[3]
See also
References
- ↑ Pitt, D.; Werner, P.; Raine, C. S. (2000). "Glutamate excitotoxicity in a model of multiple sclerosis". Nat Med. 6 (1): 67–70.
- ↑ Yamaguchi, S.; Donevan, S.D.; Rogawski, M.A. (1993). Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 15:179–184.
- ↑ Product information at Tocris
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Pages with broken file links
- Articles without UNII source
- Pages using collapsible list with both background and text-align in titlestyle
- Chemical articles using a fixed chemical formula
- AMPA receptor antagonists
- Kainate receptor antagonists
- Glycine receptor antagonists
- Sulfonamides
- Nitro compounds
- Quinoxalines
- Lactams
- Quinones
- Biochemistry stubs